Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

XOMA vs MYGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: XOMA 3 – 3 MYGN Matrix Metrics: XOMA 9 – 1 MYGN

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas MYGN carries 45.9/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About XOMA vs MYGN
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.57
-1.68% 1D
Market Cap $544.8M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.69β · 122% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 41.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.0 · SMA20: $5.94 · SMA50: $4.80

6-Pillar Scorecard Institutional Category Breakdown (XOMA 3 – 3 MYGN)

Columns: Metric · XOMA · MYGN
1. Valuation Multiples XOMA
Forward P/E 21.5x 54.0x
Trailing P/E 28.2x 54.0x
PEG Ratio N/M 1.40x
EV / Revenue 16.1x 0.8x
2. Growth & Scale MYGN
Revenue Growth (YoY) -22.6% -1.5%
Earnings Growth (YoY) +207.9% +0.0%
TTM Revenue (USD) $49M $804M
Market Cap $781.8M $544.8M
3. Profitability & Quality XOMA
Gross Margin 99.0% 68.3%
Operating Margin -3.9% -13.3%
Net Profit Margin 69.6% -16.1%
Return on Equity (ROE) 34.2% -40.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) $8.3M EBITDA -$38M
Cash Flow Margin 17.1% EBITDA Mgn -4.7%
Net Cash / Leverage $7.79 Book/Sh · 34.2% ROE $102M Net Debt (0.78x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYGN
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 101.5% (100th %ile) 124.6% (22nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity N/A 81.6% of Rev ($656M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: XOMA (9) vs MYGN (1)
Institutional Metric XOMA MYGN Criterion Row Edge
Market Capitalization
Scale
$781.8M $544.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
28.2x 54.0x Lower Multiple XOMA
Forward P/E Ratio
Valuation
21.5x 54.0x Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-22.6% -1.5% Higher Growth MYGN
Operating Margin (TTM)
Profitability
-3.9% -13.3% Higher Margin XOMA
Net Profit Margin
Profitability
69.6% -16.1% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
34.2% -40.2% Higher ROE XOMA
52-Week Range Position
Momentum
78% ($22–$45) 53% ($3–$8) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.68β · 37% Vol 0.69β · 122% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
55.8 / 100 (HOLD) 45.9 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$49M $804M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.0% 68.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 16.1x EV/Rev 1.40x PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) -$38M ($102M Net Debt (0.78x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +36.09 pp
XOMA: -3.81% · MYGN: +32.28%
3M Horizon MYGN +25.37 pp
XOMA: +9.34% · MYGN: +34.71%
6M Horizon XOMA +44.93 pp
XOMA: +34.26% · MYGN: -10.67%
1Y Horizon XOMA +32.32 pp
XOMA: +24.6% · MYGN: -7.72%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XOMA vs MYGN. Trailing 12-month operating profitability (XOMA -3.9% vs MYGN -13.3%) and valuation multiples (XOMA 21.5x vs MYGN 54.0x Forward P/E) are benchmarked directly in Pillar 4 below.

XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x
MYGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$804M
Gross Margin68.3%
Op. Margin-13.3%
ROE / Fwd P/E-40.2% · 54.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $544.8M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published

Investor FAQ XOMA vs MYGN Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). XOMA carries a Unified Composite Score of 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin), whereas MYGN carries 45.9/100 (HOLD) at $5.57 (54.0x Forward P/E, -13.3% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

MYGN leads the Growth & Scale pillar: XOMA posts -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin), compared with MYGN at -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin). On trailing 12-month operating scale, XOMA generates $49M in USD-normalized revenue versus $804M for MYGN. In operating R&D and SG&A reinvestment, XOMA deploys N/A (0 90-day corporate R&D disclosures) versus 81.6% of Rev ($656M) (0 disclosures) for MYGN.

XOMA screens cheaper on headline valuation multiples. XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin), whereas MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XOMA (34.2% ROE) versus MYGN (-40.2% ROE) capital efficiency.

In options market volatility and institutional positioning, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk). By comparison, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.69β · 122% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.